Back to Evidence
Primary experimental recordPositive observation

PMC12188416::ACT019236

tyroserleutide

Evidence text

Paper-level observation

YSL by itself exhibits limited anticancer activity, with an IC50 value of 4.34 mM (Figure S20).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Not reported by source
Measure
other
Comparator
=
Raw observation
4.34 mM
Normalized measurement
=4.34 other
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
MCF-7
Assay method
Not reported by source
Sequence
YSL
Standardization
ready simple

Source publication

Artificial Tyroserleutide Transporters for Synergistic Cancer Therapy.

JACS Au · 2025

Related peptide identities

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.